Status of p53 in first-trimester cytotrophoblastic cells

Molecular Human Reproduction

Volumn 13, Issue 2, 2007, Pages 111-116

  Cohen, M ^a   Meisser, A ^a   Haenggeli, L ^a   Irminger Finger, I ^a   Bischof, Paul ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Complex; CTB; Cytoplasm; Nucleus; p53

Indexed keywords

EPITOPE; PROTEIN P53; TETRAMER;

ARTICLE; CELL DIFFERENTIATION; CELL INVASION; CELL NUCLEUS; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOPLASM; CYTOTROPHOBLAST; EMBRYO; FEMALE; FIRST TRIMESTER PREGNANCY; GENE OVEREXPRESSION; HALF LIFE TIME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TROPHOBLAST; WESTERN BLOTTING;

CELLS, CULTURED; DIMERIZATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; TROPHOBLASTS; TUMOR SUPPRESSOR PROTEIN P53;

PYRONIA TITHONUS;

EID: 33846511265     PISSN: 13609947     EISSN: 14602407     Source Type: Journal    
DOI: 10.1093/molehr/gal105     Document Type: Article

References (28)

1. Aladjem MI, Spike BT, Rodewald LW, Hope TJ, Klemm M, Jaenisch R and Wahl GM (1998) ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Curr Biol 8,145-155.
2. Almog N and Rotter V (1997) Involvement of p53 in cell differentiation and development. Biochim Biophys Acta 1333,F1-F27.
3. Bian J and Sun Y (1997) Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 17,6330-6338.
4. Bischof P, Martelli M, Campana A, Itoh Y, Ogata Y and Nagase H (1995) Importance of matrix metalloproteinases in human trophoblast invasion. Early Pregnancy 1,263-269.
5. Bonsing BA, Corver WE, Gorsira MC, Van Viet M, Oud PS, Cornelisse CJ and Fleuren GJ (1997) Specificity of seven monoclonal antibodies against p53 evaluated with western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry. Cytometry 28,11-24.
6. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK and Lane DP (2005) p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19,2122-2137.
7. Cohen M, Meisser A and Bischof P (2006) Metalloproteinases and human placental invasiveness. Placenta 27,783-793.
8. Courtois S, Verhaegh G, North S, Luciani MG, Lassus P, Hibner U, Oren M, Hainaut P (2002) DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 21,6722-6728.
9. Courtois S, De Fromentel CC and Hainaut P (2004) p53 protein variants: structural and functional similarities with p63 and p73 isoforms. Oncogene 23,631-638.
10. El-Deiry WS, Kern S, Pietenpol JA, Kinzler KW and Vogelstein B (1992) Definition of a consensus binding site for p53. Nat Genet 1,45-49.
11. Flaman JM, Waridel F, Estreicher A, Vannier A, Limacher JM, Gilbert D, Iggo R and Frebourg T (1996) The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene 12,813-818.
12. Graham JM (1993) The identification of subcellular fractions from mammalian cells. Methods Mol Biol 19,1-18.
13. Haidacher S, Blaschitz A, Desoye G and Dohr G (1995) Immunohistochemical evidence of p53 protein in human placenta and choriocarcinoma cell lines. Hum Reprod 10,983-988.
14. Harris SL and Levine AJ (2005) The p53 pathway: Positive and negative feedback loops. Oncogene 24,2899-2908.
15. Haupt Y, Maya R, Kazaz A and Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387,296-299.
16. Kubbutat MH, Jones SN and Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387,299-303.
17. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88,323-331.
18. Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T, Sutherland A, Thorner M and Scrable H (2004) Modulation of mammalian life span by the short isoform of p53. Gene Dev 18,306-319.
19. Marzusch K, Ruck P, Horny HP, Dietl J and Kaiserling E (1995) Expression of the p53 tumour suppressor gene in human placenta: An immunohistochemical study. Placenta 16,101-104.
20. Matsumuto M, Furihata M and Ohtsuki Y (2006) Posttranslational phosphorylation of mutant p53 protein in tumor development. Med Mol Morphol 39,79-87.
21. Nickels A, Bureik M, Montenarh M, Pfreundschuh M and Koch B (1997) p53 antibodies: Call for quality. Int J Cancer 73,613-614.
22. Quenby S, Brazeau C, Drakeley A, Lewis-Jones DI and Vince G (1998) Oncogene and tumour suppressor gene products during trophoblast differentiation in the first trimester. Mol Hum Reprod 4,477-481.
23. Royds JA and Iacopetta B (2006) p53 and disease: When the guardian angel fails. Cell Death Differ 13,1017-1026.
24. Weinberg RL, Freund SM, Veprintsev DB, Bycroft M and Fersht AR (2004) Regulation of DNA binding of p53 by its C-terminal domain. J Mol Biol 342,801-811.
25. Wesierska-Gadek J, Schmid G and Cerni C (1996) ADP-ribosylation of wildtype p53 in vitro: Binding of p53 protein to specific p53 consensus sequence prevents its modification. Biochem Biophys Res Commun 224, 96-102.
26. Wu Y, Liu Y, Lee L, Miner Z and Kulesz-Martin M (1994) Wild-type alternatively spliced p53: Binding to DNA and interaction with the major p53 protein in vitro and in cells. EMBO J 13,4823-4830.
27. Yin Y, Stephen CW, Luciani MG and Fahraeus R (2002) p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 4,462-467.
28. Zaika A, Marchenko N and Moll UM (1999) Cytoplasmically "Sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation. J Biol Chem 274,27474-27480.